InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（0 笔）
内部人交易记录
首席财务官已披露买入
0
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
无可用的信号评分。
Browse the detailed record of transactions filed by Silberman David, 首席财务官. Officer active across 2 companies, notably Oramed Pharmaceuticals INC.. In total, 7 filings have been published. Activity tracked since 1 September 2021. The latest transaction was disclosed on 29 July 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Silberman David
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报7 总计
19,500 股0Ordinary SharesSEC:0001178913-26-003727:0
136,500 股Common StockSEC:0001209191-24-001146:0
24,500 股Common StockSEC:0001209191-23-033141:0
97,500 股Common StockSEC:0001209191-23-024936:0
39,000 股Common StockSEC:0001209191-22-043765:0
19,000 股Common StockSEC:0001213900-22-000805:0
50,000 股0Common StockSEC:0001213900-21-046413:0
7 条申报中的 7 条
About Silberman David
Silberman David is Chief Financial Officer at Oramed Pharmaceuticals INC. and COMPUGEN LTD. He has 7 filings in total, and across the 7 sampled filings the transactions are of Attribution nature, with a period ranging from 2021-09-02 to 2026-07-30 and buy and sell amounts of EUR 0.
